Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 601–700 of 999
Ras‐Driven Transformation of Human Nestin‐Positive Pancreatic Epithelial Cells
Campbell, P. M., Lee, K. M., Ouellette, M. M., Kim, H. J., Groehler, A. L., Khazak, V., & Der, C. J. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)00431-4 · Cited by 24
Tumor Antigen-Based Immunotherapy and Immunoprevention of Cancer
Ryan, S. O., Gantt, K. R., & Finn, O. J. (2006) · International Archives of Allergy and Immunology · doi:10.1159/000097020 · Cited by 23
Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
Hayashi, H., Uemura, N., Liu, Z., Matsumura, K., Sato, H., Shiraishi, Y., & Baba, H. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700315 · Cited by 28
Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles
Blanco, V., Latif, T., Chu, Z., & Qi, X. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.03.011 · Cited by 23
“A signature molecular profile has emerged from genetic studies, identifying activating mutations in the oncogene KRAS and inactivating mutations in the tumor suppressors CDKN2A, TP53, and SMAD4/DPC4, as the main drivers of pancreatic carcinogenesis [13,14].”
Background清水一也, Itoh, T., Shimizu, M., Ku, Y., & Hori, Y. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181bb5037 · Cited by 27
Deng, M., Chen, P.-C., Xie, S., Zhao, J., Gong, L., Liu, J., Zhang, L., Sun, S., Liu, J., Ma, H., et al. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.04.004 · Cited by 23
Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models
DeCant, B. T., Principe, D. R., Guerra, C. E., di Magliano, M. P., & Grippo, P. J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00464 · Cited by 24
“These LSL-KrasG12D;Ink4a/Arf flox/flox;Pdx1-Cre mice presented with invasive, metastatic disease consistent with human disease (Aguirre et al., 2003).”
BackgroundDer, C. J., & Dyke, T. V. (2007) · Cell · doi:10.1016/j.cell.2007.05.031 · Cited by 25
“Second, will Ras-driven oncogenesis in other mouse cancer models—in particular in K-Ras-induced pancreatic tumor formation models (Aguirre et al., 2003; Hingorani et al., 2003)—also require p110α?”
BackgroundSULF1/SULF2 splice variants differentially regulate pancreatic tumour growth progression
Gill, R. M. S., Michael, A., Westley, L., Kocher, H. M., Murphy, J. I., & Dhoot, G. K. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.04.001 · Cited by 25
Rozengurt, E., & Eibl, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i15.1797 · Cited by 22
Molkentine, J. M., Fujimoto, T. N., Horvath, T. D., Grossberg, A. J., García, C. J. G., Deorukhkar, A., Bonilla, M. D. L. C., Lin, D., Samuel, E. L. G., Chan, W., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37147-9 · Cited by 22
Human pancreatic cancer progression: an anarchy among CCN-siblings
Banerjee, S. K., Maity, G., Haque, I., Ghosh, A., Sarkar, S., Gupta, V. G., Campbell, D. R., Hoff, D. D. V., & Banerjee, S. (2016) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0343-9 · Cited by 26
Liao, J. D., Adsay, V. N., Khannani, F., Grignon, D. J., Thakur, A. B., & Sarkar, F. H. (2007) · PubMed · doi:10.14670/hh-22.661 · Cited by 22
Genetically modified organoids for tissue engineering and regenerative medicine
Zhang, Q., Jin, H., Zhu, D., Chen, Y., Fu, M., Lu, S., Qiu, Y., Zhou, G., Yang, G., & Jiang, Z. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103337 · Cited by 26
ERK2-regulated TIMP1 Induces Hyperproliferation of K-RasG12D-Transformed Pancreatic Ductal Cells
Botta, G. P., Reichert, M., Reginato, M. J., Heeg, S., Rustgi, A. K., & Lelkes, P. I. (2013) · Neoplasia · doi:10.1593/neo.121708 · Cited by 22
“[35] Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS,”
BackgroundMa, Y., Schulz, B., Trakooljul, N., Alammar, M., Sekora, A., Sender, S., Hadlich, F., Zechner, D., Weiß, F. U., Lerch, M. M., et al. (2022) · Cancers · doi:10.3390/cancers14184467 · Cited by 24
A molecular pathway for cancer cachexia-induced muscle atrophy revealed at single-nucleus resolution
Zhang, Y., Santos, M. D., Huang, H., Chen, K., Iyengar, P., Infante, R. E., Polanco, P. M., Brekken, R. A., Cai, C., Caijgas, A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114587 · Cited by 28
Modeling cancer patient populations in mice: Complex genetic and environmental factors
Radiloff, D. R., Rinella, E. S., & Threadgill, D. W. (2007) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2007.06.004 · Cited by 21
“These two mutations occur in almost all cases of human pancreatic adenocarcinomas, yet mice expressing Kras only display signs of early stage pancreatic tumor growth while mice lacking Cdkn2a have no neoplastic lesions in the pancreas.”
BackgroundLigat, L., Saint‐Laurent, N., Mrani, A. E., Gigoux, V., Saati, T. A., Tomasini, R., Nigri, J., Dejean, S., Pont, F., Baer, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.370 · Cited by 20
“The conditional Ink4a/Arflox/lox mouse strain was from Ronald A. DePinho’s laboratory (Aguirre et al, 2003).”
MethodAnimal models for modeling pancreatic cancer and novel drug discovery
Bisht, S., & Feldmann, G. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1566319 · Cited by 22
“For example, DePinho and coworkers demonstrated that in combination with oncogenic Kras expression, homozygous inactivation of p16(Ink4a)/p19 (Arf) led to rapid development of aggressively invading, mostly poorly differentiated murine pancreatic cancers with short latency in Pdx1-Cre; LsL-Kras; Ink4a/Arf mice, resulti…”
BackgroundMeyers, N., Gérard, C., Lemaigre, F. P., & Jacquemin, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-62106-8 · Cited by 19
Zhang, N., Lyons, S. K., Lim, E., & Lassota, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2256 · Cited by 23
“The application of other promoters such as p48 and Pdx for mediating ductal cell–specific gene expression have since been published (27, 28 ).”
BackgroundQuan, S., Principe, D. R., Dean, A. E., Park, S., Grippo, P. J., Gius, D. R., & Horikoshi, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-34792-y · Cited by 21
Hahn, W. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.007 · Cited by 23
Ramesh, R. P. G., Yasmin, H., Ponnachan, P., al-Ramadi, B. K., Kishore, U., & Joseph, A. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573522 · Cited by 22
Macrophages-induced IL-18–mediated eosinophilia promotes characteristics of pancreatic malignancy
Kandikattu, H. K., Manohar, M., Verma, A. K., Kumar, S., Yadavalli, C. S., Venkateshaiah, S. U., & Mishra, A. (2021) · Life Science Alliance · doi:10.26508/lsa.202000979 · Cited by 20
“…in various settings with additional mutations, including deletion or inactivation of p53 or TGF-β signaling molecule SMAD4, is signi fi cant in tumor development and, in some instances, acquisition of metastatic properties (Aguirre et al, 2003; Tuveson & Hingorani, 2005; Bardeesy et al, 2006).”
Shu, Z., Fan, M., Tu, B., Tang, Z., Wang, H., Li, H., Li, H., Yuan, M., Bai, J., Huo, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42508-8 · Cited by 20
Shai, A., Dankort, D. L., Juan, J. M., Green, S., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3701 · Cited by 23
“Cancer Res; 75(15) August 1, 2015 Cancer Research 3172”
InfluentialChallenges in developing targeted therapy for pancreatic adenocarcinoma
Mahalingam, D., & Giles, F. J. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.11.1389 · Cited by 21
“Based on the known genetic alteration in human pancreatic cancer, transgenic mouse models with different genetic changes have been generated that mimic human pancreatic cancer [67-71] .”
BackgroundCollignon, A., Perles‐Barbacaru, T., Robert, S., Silvy, F., Martinez, E., Crenon, I., Germain, S., Garcia, S., Viola, A., Lombardo, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4359 · Cited by 20
“Genetically-engineered mouse models (Pdx-1Cre/KrasG12D/Ink4a/Arflox/lox and Pdx-1-Cre; LSL-KrasGD12; LSL-Trp53R172H mice), which develop pancreatic tumors [44, 45], could not be used since the tested tumors showed no reactivity to mAbJ28.”
Knab, L. M., Ebine, K., Chow, C. R., Raza, S. S., Sahai, V., Patel, A. P., Kumar, K., Bentrem, D. J., Grippo, P. J., & Munshi, H. G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0111 · Cited by 20
“expression of embryonic mutant K-ras is sufficient for tumor initiation in various mouse models of pancreatic cancer (41, 42), expression of mutant K-ras in adult mouse pancreas does not result in any obvious phenotypic changes (15).”
BackgroundDorf, J., Zaręba, K. P., Guzińska-Ustymowicz, K., Kędra, B., Kemonä, A., & Pryczynicz, A. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1751-z · Cited by 23
“Moreover, studies performed onmouse models revealed that deletion and consequently inactivation of p16INK4A greatly accelerated the malignant progression of mutant K-ras-triggered PanIN lesions into highly invasive or metastatic PDAC after activation ofK-ras gene which is responsible for the development of pancreatic…”
BackgroundZebrafish model of KRAS-initiated pancreatic cancer
Park, J. T., & Leach, S. D. (2018) · Animal Cells and Systems · doi:10.1080/19768354.2018.1530301 · Cited by 24
“The dramatic progress of mouse models for pancreatic cancer arouses the expectation that these models could be used to develop a new drug against PDAC, as preclinical trials of anticancer drugs in animal models constitute an important step in the drug development (Aguirre et al. 2003; Hingorani et al. 2003; Hruban et…”
BackgroundTakahashi, R., Ijichi, H., Sano, M., Miyabayashi, K., Mohri, D., Kim, J., Kimura, G., Nakatsuka, T., Fujiwara, H., Yamamoto, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78320-3 · Cited by 22
The pancreatic cancer proteome – recent advances and future promise
Aspinall-O’Dea, M., & Costello, E. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700144 · Cited by 20
Workshop on imaging science development for cancer prevention and preemption
Kelloff, G. J., Sullivan, D. C., Baker, H., Clarke, L., Nordstrom, R. J., Tatum, J. L., Dorfman, G. S., Jacobs, P. M., Berg, C. D., Pomper, M. G., et al. (2006) · Cancer Biomarkers · doi:10.3233/cbm-2007-3101 · Cited by 20
“New and better animal models of pancreatic cancer [2,74] provide test environments to evaluate these rationally designed diagnostic and treatment candidates.”
Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis—A connection to licensing nodes
Schneeweis, C., Wirth, M., Saur, D., Reichert, M., & Schneider, G. (2016) · Small GTPases · doi:10.1080/21541248.2016.1262935 · Cited by 21
Weaknesses and Pitfalls of Using Mice and Rats in Cancer Chemoprevention Studies
Ma, Y., Jia, Y., Chen, L., Ezeogu, L., Yu, B., Xu, N., & Liao, D. J. (2015) · Journal of Cancer · doi:10.7150/jca.12519 · Cited by 19
“In those animal models that contain two, three or even more different transgenes driven by different promoters, such as in the MMTV-myc/MT-tgfα double transgenic [31;32] and the LSL-KrasG12D/ pdx-cre/Arf-/- triple transgenic mice [33], producing pups that bear all different transgenes is highly costly and laborious, b…”
BackgroundYao, C., Yu, H., Zhou, G., Xu, J., Gu, D., Li, Y., He, X., & Xia, H. (2021) · Esophagus · doi:10.1007/s10388-021-00828-y · Cited by 20
Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening
Badheeb, M. A., Abdelrahim, A., Esmail, A., Umoru, G., Abboud, K., Al-Najjar, E., Rasheed, G. O., Alkhulaifawi, M., Abudayyeh, A., & Abdelrahim, M. (2022) · Current Oncology · doi:10.3390/curroncol29110686 · Cited by 23
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B. C., Fisher, G. A., Kunz, P. L., Ford, J. M., Koong, A. C., & Pai, R. K. (2010) · Cancer · doi:10.1002/cncr.25481 · Cited by 21
“In mouse models, activating K-rasmutations associated with inactivation of the p16 gene give rise to an earlier appearance of PanIn lesions within mice and rapid progression to highly invasive carcinomas with metastatic disease.(27,28) In addition, Wilentz and colleagues found that loss of Figure 3.”
BackgroundLi, D., Schaub, N. P., Guerin, T. M., Bapiro, T. E., Richards, F. M., Chen, V., Talsania, K., Kumar, P., Gilbert, D. J., Schlomer, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0620 · Cited by 20
“Mice with individual alleles for Pdx-1-cre, LSLKras G12D/+ , and Ink4a(p16)/Arf(p19) flox/flox or LSL-Trp53 R172H/+ were crossed to create animals with the triple genotype Pdx-1-cre;LSL-Kras G12D/+ ;Ink4a(p16)/Arf(p19) flox/flox (KP16) or Pdx-1cre;LSL-Kras G12D/+ ;LSL-Trp53 R172H/+ (KPC) (20, 21).”
Acier, A., Godard, M., Gassiot, F., Finetti, P., Rubis, M., Nowak, J., Bertucci, F., Iovanna, J., Tomasini, R., Lécorché, P., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02508-0 · Cited by 20
NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma
Ramakrishnan, G., Parajuli, P., Singh, P., Friend, C., Hurwitz, E. G., Prunier, C., Razzaque, M. S., Xu, K., & Atfi, A. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111623 · Cited by 20
Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
Khan, S. U., Budamagunta, V., & Zhou, D. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.004 · Cited by 23
Rajbhandari, N., Hamilton, M., Quintero, C. M., Ferguson, L. P., Fox, R. G., Schürch, C. M., Wang, J., Nakamura, M., Lytle, N. K., McDermott, M. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.008 · Cited by 17
Fan, M., Huo, S., Guo, Y., Wang, R., Hao, W., Zhang, Z., Wang, L., & Zhao, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113808 · Cited by 18
Efficient and multiplexed somatic genome editing with Cas12a mice
Hebert, J. D., Xu, H., Tang, Y. J., Ruiz, P. A., Detrick, C. R., Wang, J., Hughes, N. W., Donosa, O., Siah, V. P., Andrejka, L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01407-7 · Cited by 21
Higuchi, T., Yokobori, T., Naito, T., Kakinuma, C., Hagiwara, S., Nishiyama, M., & Asao, T. (2017) · Oncology Letters · doi:10.3892/ol.2017.7722 · Cited by 18
Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus
Tang, Z., Chu, Y., Tan, Y., Li, J., & Gao, S. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000628 · Cited by 19
Bam, R., Daryaei, I., Abou‐Elkacem, L., Vilches-Moure, J. G., Meuillet, E. J., Lutz, A. M., Marinelli, E. R., Unger, E. C., Gambhir, S. S., & Paulmurugan, R. (2020) · Investigative Radiology · doi:10.1097/rli.0000000000000697 · Cited by 17
“Contrast-enhanced US is a promising imaging technology with a high potential to detect and aid human pancreatic cancer treatment using contrast agents.10–12 A pooled meta-analysis of contrast-enhanced transabdominal US and EUS showed high sensitivity (0.89) and specificity (0.84) for the diagnosis of PDAC.13 Ultrasoun…”
MethodInfluentialThe Dual Role of Senescence in Pancreatic Ductal Adenocarcinoma
Porciuncula, A., Hajdu, C. H., & David, G. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.006 · Cited by 20
Oristian, K. M., Crose, L. E. S., Kuprasertkul, N., Bentley, R. C., Lin, Y.-T., Williams, N. T., Kirsch, D. G., & Linardic, C. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3912 · Cited by 18
“Cdkn2a (Ink4a/Arf) mice were provided by Ron DePinho, and have been described (8,9).”
Zhang, Y., Kirane, A., Huang, H., Sorrelle, N. B., Burrows, F. J., Dellinger, M. T., & Brekken, R. A. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0427 · Cited by 23
“Kras; Cdkn2a; Ptf1aCre/þ (KIC) mice were generated as previously described (35).”
MethodMice develop normally in the absence of Smad4 nucleocytoplasmic shuttling
Biondi, C., Das, D., Howell, M. T., Islam, A., Bikoff, E. K., Hill, C. S., & Robertson, E. J. (2007) · Biochemical Journal · doi:10.1042/bj20061830 · Cited by 18
Rabi, T., & Catapano, C. V. (2016) · Tumor Biology · doi:10.1007/s13277-016-5102-2 · Cited by 18
The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
Low, R. R. J., Lim, W., Nguyen, P. M., Lee, B., Christie, M., Burgess, A. W., Gibbs, P., Grimmond, S. M., Hollande, F., & Putoczki, T. L. (2021) · Cancers · doi:10.3390/cancers13194979 · Cited by 20
Zhang, J. H., Darman, L., Hassan, M. S., von Holzen, U. W., & Awasthi, N. (2023) · Oncology Reports · doi:10.3892/or.2023.8643 · Cited by 24
“Furthermore, Aguirre et al reported that the KRAS G12D mutation alone formed PanIN and the protracted onset of PDAC (7).”
BackgroundOncolytic viral therapy for pancreatic cancer: current research and future directions
Fong, Y., Ady, J., Heffner, J., & Klein, E. (2014) · Oncolytic Virotherapy · doi:10.2147/ov.s53858 · Cited by 22
Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer
Kuo, K., Hsiao, P., Chang, W., Chuang, S., Yang, Y.-H., Wuputra, K., Ku, C., Pan, J.-B., Li, C.-P., Kato, K., et al. (2021) · Cancers · doi:10.3390/cancers13153920 · Cited by 18
“tumors become high-grade PanIN-3 lesions [7,19,20].”
BackgroundThe secret origins and surprising fates of pancreas tumors
Bailey, J. M., DelGiorno, K. E., & Crawford, H. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu056 · Cited by 23
“The initial mouse modeling experiments used the Pdx1-Cre or Ptf1aCre/+ mouse driver lines to initiate Kras* expression in embryonic pancreatic progenitor cells (12,18).”
MethodA rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics
Ocal, O., Pashkov, V., Kollipara, R. K., Zolghadri, Y., Cruz, V. H., Hale, M. A., Heath, B. R., Artyukhin, A. B., Christie, A. L., Tsoulfas, P., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.020933 · Cited by 21
“KIC mice are an excellent GEMM for PDA therapeutic screens because neoplasia develops early, between 2 to 3 weeks of age, and large aggressive tumors develop in all mice by 4 weeks of age (Aguirre et al., 2003).”
BackgroundMethodInfluentialKishikawa, T., Otsuka, M., Suzuki, T., Seimiya, T., Sekiba, K., Ishibashi, R., Tanaka, E., Ohno, M., Yamagami, M., & Koike, K. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0139 · Cited by 18
Chemical genetic screening of KRAS-based synthetic lethal inhibitors for pancreatic cancer
Ji, Z. (2009) · Frontiers in bioscience · doi:10.2741/3421 · Cited by 17
“Targeted endogenous expression of an oncogenic KRAS allele in the mouse pancreas is sufficient to drive the development of PanINs, and subsequently, at low frequency, the progression to both locally invasive adenocarcinoma and metastatic disease with sites of spread exactly as found in human pancreatic cancer (1;12;13…”
BackgroundK‐RasV14I‐induced Noonan syndrome predisposes to tumour development in mice
Hernández‐Porras, I., Schuhmacher, A. J., Garcia‐Medina, R., Jiménez, B., Cañamero, M., de Martino, A., & Guerra, C. (2016) · The Journal of Pathology · doi:10.1002/path.4719 · Cited by 16
“Although K-Ras oncogenes and p16Ink4a/p19Arf loss cooperate, accelerating PDAC and lung tumour development in mouse models [34,45,46], no other tumours were found in K-RasV14I;p16Ink4a/p19Arf −/− mice.”
BackgroundLi, J., Wei, T., Zhang, J., & Liang, T. (2021) · Cancers · doi:10.3390/cancers13215296 · Cited by 19
“A widely used classical mouse model to elicit mPanIN that can further progress to PDAC (latency of >1 y) [75] is based on the KRAS mutation, which strongly stimulates its intrinsically inefficient activity [76].”
BackgroundCDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
Arsenijevic, T., Coulonval, K., Raspé, E., Demols, A., Roger, P. P., & Laethem, J. V. (2023) · Cancers · doi:10.3390/cancers15030968 · Cited by 21
“PDAC might ave the ig est probability of initial sensitivity to CDK4/6 inhibitors due to the freque t alteration of the CDKN2A locus through mutations, deletions, or epigenetic silencing, as well as an intact RB locus [87,88].”
BackgroundElango, A., Nesam, V. D., Sukumar, P., Lawrence, I., & Radhakrishnan, A. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-03914-8 · Cited by 15
“Reports indicate that Kras combines with CDKN2A, a tumor suppressor gene and develops PDAC (Aguirre et al. 2003).”
Molecular Alterations in Exocrine Neoplasms of the Pancreas
Ranganathan, P., Gowda, H., & Pandey, A. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.405 · Cited by 20
Paisie, C. A., Schrock, M. S., Karras, J. R., Zhang, J., Miuma, S., Ouda, I. M., Waters, C. E., Saldivar, J. C., Druck, T., & Huebner, K. (2016) · Cancer Science · doi:10.1111/cas.12887 · Cited by 16
Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer
Chuang, H.-C., Huang, P.-H., Kulp, S. K., & Chen, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.006 · Cited by 17
Hsieh, M.-J., Chiu, T., Lin, Y. C., Weng, C., Weng, Y., Hsiao, C., & Cheng, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124473 · Cited by 17
“This model recapitulated the multistep progression of the cognate human disease, including the presence of mouse PanIN (mPanINs) at various histological grades [28,29].”
BackgroundMira, J. M., Sapre, A. A., Walker, B. S., Bueno, J., Gustafson, K. T., Tu, E. L., Fischer, J. M., Wong, M. H., Esener, S. C., & Chiu, Y. (2021) · Communications Biology · doi:10.1038/s42003-021-02651-8 · Cited by 19
Study human pancreatic cancer in mice: How close are they?
Zhang, Y., Chen, L. L., Yang, J., Fleming, J. B., Chiao, P. J., Logsdon, C. D., & Li, M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.11.001 · Cited by 19
“Mice with a pancreas-specific deletion of INK4a/ARF or TP53 alone do not result in pancreatic neoplasia, but when combined with K-Ras, not only did the mice developed invasive PDAC by 7–11 weeks, the tumor was developed in a more aggressive fashion with metastasis, shorter latency and complete penetrance [64].”
Long, J., Zhang, Z., Liu, Z., Xu, Y., & Ge, C. (2015) · Oncology Letters · doi:10.3892/ol.2015.4042 · Cited by 16
Characterization of Stem-like Circulating Tumor Cells in Pancreatic Cancer
Zhu, L., Hissa, B., Győrffy, B., Jann, J.-C., Yang, C., Reißfelder, C., & Schölch, S. (2020) · Diagnostics · doi:10.3390/diagnostics10050305 · Cited by 17
Mathieu, A., Clerc, P., Portolan, G., Bierkamp, C., Lulka, H., Pradayrol, L., Seva, C., Fourmy, D., & Dufresne, M. (2005) · International Journal of Cancer · doi:10.1002/ijc.20861 · Cited by 16
“However, as already previously demonstrated in vitro in immortalized duct cells, cooperating additional genotoxic events are needed for progression of cancer.(48,49) In the current study, the fact that aza-”
BackgroundSenescence program and its reprogramming in pancreatic premalignancy
Yang, K., Li, X., & Xie, K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06040-3 · Cited by 21
“KRAS is the first and most commonly detected genetic mutation in PDA [91, 92].”
BackgroundDecoding the obesity–cancer connection: lessons from preclinical models of pancreatic adenocarcinoma
Ruiz, C. F., Garcia, C. C., Jacox, J. B., Lawres, L., & Muzumdar, M. D. (2023) · Life Science Alliance · doi:10.26508/lsa.202302228 · Cited by 17
“…Kras expression in the mouse pancreas (Table 1) stimulates the formation of preinvasive pancreatic intraepithelial neoplasia (PanINs) capable of progressing to advanced PDAC (Aguirre et al, 2003; Hingorani et al, 2003; Hingorani et al, 2005; Guerra et al, 2007; Habbe et al, 2008; Kopp et al, 2012).”
BackgroundDifferentiation and Inflammation: ‘Best Enemies’ in Gastrointestinal Carcinogenesis
Krah, N. M., & Murtaugh, L. C. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.005 · Cited by 16
Zebrafish model of KRAS-initiated pancreatic endocrine tumor
Oh, S., & Park, J. T. (2019) · Animal Cells and Systems · doi:10.1080/19768354.2019.1610058 · Cited by 15
“KRAS-mediated pancreatic cancer have successfully replicated the early and advanced forms of this disease (Aguirre et al. 2003; Hingorani et al. 2003; Hruban et al. 2006).”
BackgroundModels of pancreatic ductal adenocarcinoma
Dennaoui, R., Shrestha, H., & Wagner, K. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09989-9 · Cited by 20
Algül, H., Wagner, M., Lesina, M., & Schmid, R. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.22779 · Cited by 15
“oncogenic KRAS has been expressed in the pancreas.(33) There-”
BackgroundTakahashi, M., Mutoh, M., Ishigamori, R., Fujii, G., & Imai, T. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0340-x · Cited by 18
“Furthermore, these mice were modified by conditional deletions or mutations of p16 [228], p53 [229], dpc4 [230], and TGF −β receptor II [231].”
BackgroundEffect of arenobufagin on human pancreatic carcinoma cells
Wang, T., Zhuang, Z., Zhang, P., Wang, Y., Mu, L., Jin, H., Zhou, L., Ma, X., Liang, R., & Yuan, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6798 · Cited by 17
SOX9 modulates cancer biomarker and cilia genes in pancreatic cancer
Edelman, H. E., McClymont, S. A., Tucker, T. R., Pineda, S. B., Beer, R. L., McCallion, A. S., & Parsons, M. J. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab064 · Cited by 15
Differential Sensitivity of Mouse Epithelial Tissues to the Polyomavirus Middle T Oncogene
Ceceña, G., Wen, F., Cardiff, R. D., & Oshima, R. G. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050443 · Cited by 15
Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer
Chu, P., Kulp, S. K., Bekaii‐Saab, T., & Chen, C. (2016) · Small GTPases · doi:10.1080/21541248.2016.1251383 · Cited by 15
A Cancer Cell Cluster Marked by LincRNA MEG3 Leads Pancreatic Ductal Adenocarcinoma Metastasis
Pan, H., Diao, H., Zhong, W., Wang, T., Wen, P., & Wu, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.656564 · Cited by 15
“Elevated MEG3 in Cancer Cells of PDAC Mouse Models To further study the functions of MEG3 in the progression of PDAC, we re-accessed the scRNA-seq data (17) on three commonly used PDAC mouse models (KIC, Kras Ink4aPtf1a; KPfC, KrasTrp53Pdx1; KPC, KrasTrp53Ptf1a) (30, 31) and normal pancreatic tissues from a recently p…”
MethodSaxena, S., Molczyk, C., Purohit, A., Ehrhorn, E. G., Goel, P., Prajapati, D. R., Atri, P., Kaur, S., Grandgenett, P. M., Hollingsworth, M. A., et al. (2022) · PubMed · Cited by 17
Pericyte stem cells induce Ly6G+ cell accumulation and immunotherapy resistance in pancreatic cancer
Wu, Z., Thierry, K., Bachy, S., Zhang, X., Gamradt, P., Hernández‐Vargas, H., Mikaélian, I., Tonon, L., Pommier, R. M., Zhao, Y., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256524 · Cited by 16
“…in mice with PDAC, that is, pdx1 -Cre; Kras G12D ; Ink4a / Arf fl/fl (KIC; Unpublished observations, Wu), and pdx1 -Cre; Kras G12D ; p53 R172H (KPC) mice (Fig 1D, right), which develop adenocarcinoma beginning at 5 and 16 weeks of age, respectively (Aguirre et al , 2003; Hingorani et al , 2005).”
In vivo models of pancreatic ductal adenocarcinoma
Vudatha, V., Herremans, K. M., Freudenberger, D. C., Liu, C., & Trevino, J. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.002 · Cited by 19
Sensitization of Human Pancreatic Cancer Cells Harboring Mutated K-ras to Apoptosis
Shen, L., Kim, S., & Chen, C. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040435 · Cited by 15
“Although a variety of genetic aberrant markers have been identified in human pancreatic cancer lesions, the most frequent mutations were identified in K-ras, and the closely following events were the inactivation of the tumor suppressors of p16, ARF, p53 and SMAD4 [12–14].”
BackgroundInfluentialPancreatic Cancer: Translating Lessons from Mouse Models and Hereditary Syndromes
Wescott, M. P., & Rustgi, A. K. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0195 · Cited by 14
Runx3 and Cell Fate Decisions in Pancreas Cancer
Whittle, M. C., & Hingorani, S. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_21 · Cited by 14
Novel Targets in Pancreatic Cancer Therapy - Current Status and Ongoing Translational Efforts
Bisht, S., & Feldmann, G. (2018) · Oncology Research and Treatment · doi:10.1159/000493437 · Cited by 14
The Sag-Shoc2 axis regulates conversion of mPanINs to cystic lesions in Kras pancreatic tumor model
Tan, M., Chang, Y., Liu, X., Li, H., Tang, Z., Nyati, M. K., & Sun, Y. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111837 · Cited by 14
Fu, T., Guzzetta, A. A., Jeschke, J., Vatapalli, R. J., Dave, P., Hooker, C. M., Morgan, R., Iacobuzio–Donahue, C. A., Liu, B., & Ahuja, N. (2012) · International Journal of Cancer · doi:10.1002/ijc.27910 · Cited by 15
Chromosomal instability in mouse metastatic pancreatic cancer—it’s Kras and Tp53 after all
Siveke, J. T., & Schmid, R. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.025 · Cited by 20
Ma, L., & Saiyin, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176844 · Cited by 14
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.